Get the Latest Investment Ideas Delivered Straight to Your Inbox. Subscribe

TICKERS: BPTH

Texas Biotech Advances Lead Candidate in Resistant AML
Research Report

View Important Disclosures for this Article
Share on Stocktwits

Source:

Recently, Texas-based biotech Bio-Path Holdings Inc. announced it had completed the first safety cohort of a Phase 1/1b trial evaluating the developmental drug BP1002 in acute myeloid leukemia (AML). Read on to see what one Roth analyst has to say about the company's stock.

Bio-Path Holdings Inc. (BPTH:NASDAQ) recently completed the first safety cohort of a Phase 1/1b trial evaluating the developmental drug BP1002 in acute myeloid leukemia (AML), noted Roth MKM analyst Dr. Jonathan Aschoff in a December 14 research note.

One cohort showed no dose-limiting toxicity, clearing the way for further dose escalation in relapsed/refractory patients.

BP1002 targets Bcl-2 to potentially overcome venetoclax-resistance. With venetoclax use rising, the addressable population resistant to that therapy may expand over time. BP1002 inhibits Bcl-2 via a distinct mechanism from venetoclax while aiming to rescue refractory patients.

As first doses often have limited efficacy, Roth analyst Jonathan Aschoff expects improved outcomes in subsequent higher-dose cohorts. To date, Bio-Path's pipeline demonstrates a "highly favorable safety profile" across evaluated dose levels.

Upon completing the Phase 1 monotherapy segment, Bio-Path will initiate a Phase 1b portion combining BP1002 with decitabine. This regimen will be evaluated in the same AML population.

Valuation and Upside
Roth maintains a Buy rating and US$12 price target on Bio-Path based on discounted cash flow projections. This target implies over 2,300% upside from current levels, around US$0.49.


Want to be the first to know about interesting Biotechnology / Pharmaceuticals investment ideas? Sign up to receive the FREE Streetwise Reports' newsletter. Subscribe

Important Disclosures:

  1. The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
  2. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

Disclosures for Roth MKM, Bio-Path Holdings Inc., December 14, 2023

Regulation Analyst Certification ("Reg AC"): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Disclosures: Within the last twelve months, ROTH Capital Partners, or an affiliate to ROTH Capital Partners, has received compensation for investment banking services from Bio-Path Holdings, Inc. ROTH makes a market in shares of Bio-Path Holdings, Inc and as such, buys and sells from customers on a principal basis. Shares of Bio-Path Holdings, Inc may be subject to the Securities and Exchange Commission's Penny Stock Rules, which may set forth sales practice requirements for certain low-priced securities.

ROTH Capital Partners, LLC expects to receive or intends to seek compensation for investment banking or other business relationships with the covered companies mentioned in this report in the next three months. The material, information and facts discussed in this report other than the information regarding ROTH Capital Partners, LLC and its affiliates, are from sources believed to be reliable, but are in no way guaranteed to be complete or accurate. This report should not be used as a complete analysis of the company, industry or security discussed in the report. Additional information is available upon request. This is not, however, an offer or solicitation of the securities discussed. Any opinions or estimates in this report are subject to change without notice. An investment in the stock may involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Additionally, an investment in the stock may involve a high degree of risk and may not be suitable for all investors. No part of this report may be reproduced in any form without the express written permission of ROTH. Copyright 2023. Member: FINRA/SIPC.





Want to read more about Biotechnology / Pharmaceuticals investment ideas?
Get Our Streetwise Reports' Research Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe